COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENTCollaborative Research and Development and License Agreement • November 3rd, 2009 • Optimer Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledNovember 3rd, 2009 Company Industry JurisdictionTHIS COLLABORATIVE RESEARCH AND DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of March 31, 2006 (the “Effective Date”) by and between OPTIMER PHARMACEUTICALS INC., a Delaware corporation with its offices located at 10110 Sorrento Valley Road, Suite C, San Diego, California 92121 (“Optimer”), and CEMPRA PHARMACEUTICALS, INC., a Delaware corporation with its offices located at 170 Southport Drive, Suite 500, Morrisville, NC 27560. Optimer and Cempra may be referred to herein individually as a “Party” or collectively, as the “Parties.”
INTELLECTUAL PROPERTY ASSIGNMENT AND LICENSE AGREEMENTIntellectual Property Assignment and License Agreement • November 3rd, 2009 • Optimer Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledNovember 3rd, 2009 Company Industry JurisdictionTHIS INTELLECTUAL PROPERTY ASSIGNMENT AND LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of October 30, 2009 (the “Effective Date”) by and between OPTIMER PHARMACEUTICALS, INC., a Delaware corporation (“Optimer”), and OPTIMER BIOTECHNOLOGY, INC., a Taiwan corporation (“OBI”).
FINANCING AGREEMENTFinancing Agreement • November 3rd, 2009 • Optimer Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledNovember 3rd, 2009 Company Industry JurisdictionTHIS FINANCING AGREEMENT (this “Agreement”) is made and entered into as of October 30, 2009, by and among OPTIMER BIOTECHNOLOGY, INC., a Taiwan corporation (the “Company”), and each of those persons and entities, severally and not jointly, whose names are set forth on the Schedule of Purchasers attached hereto as EXHIBIT A (which persons and entities are hereinafter collectively referred to as “Purchasers” and each individually as a “Purchaser”).